- Home
- JYD vs CMPS Comparison
JYD vs CMPS Comparison
Compare JYD & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYD
- CMPS
- Stock Information
- Founded
- JYD 2001
- CMPS 2020
- Country
- JYD China
- CMPS United Kingdom
- Employees
- JYD N/A
- CMPS N/A
- Industry
- JYD Oil Refining/Marketing
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- JYD Consumer Discretionary
- CMPS Health Care
- Exchange
- JYD Nasdaq
- CMPS Nasdaq
- Market Cap
- JYD 390.7M
- CMPS 422.4M
- IPO Year
- JYD 2023
- CMPS 2020
- Fundamental
- Price
- JYD $4.03
- CMPS $4.21
- Analyst Decision
- JYD
- CMPS Strong Buy
- Analyst Count
- JYD 0
- CMPS 6
- Target Price
- JYD N/A
- CMPS $29.60
- AVG Volume (30 Days)
- JYD 129.6K
- CMPS 1.2M
- Earning Date
- JYD 03-26-2025
- CMPS 02-27-2025
- Dividend Yield
- JYD N/A
- CMPS N/A
- EPS Growth
- JYD N/A
- CMPS N/A
- EPS
- JYD N/A
- CMPS N/A
- Revenue
- JYD $82,427,232.00
- CMPS N/A
- Revenue This Year
- JYD N/A
- CMPS N/A
- Revenue Next Year
- JYD N/A
- CMPS N/A
- P/E Ratio
- JYD N/A
- CMPS N/A
- Revenue Growth
- JYD 63.05
- CMPS N/A
- 52 Week Low
- JYD $0.42
- CMPS $3.17
- 52 Week High
- JYD $5.01
- CMPS $12.75
- Technical
- Relative Strength Index (RSI)
- JYD 56.41
- CMPS 48.38
- Support Level
- JYD $3.55
- CMPS $3.99
- Resistance Level
- JYD $4.43
- CMPS $4.88
- Average True Range (ATR)
- JYD 0.44
- CMPS 0.41
- MACD
- JYD -0.07
- CMPS -0.01
- Stochastic Oscillator
- JYD 37.23
- CMPS 26.89
About JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is a end-to-end supply chain solution providers in China, with a focus on providing cross-border logistics services. It offers freight forwarding services, (ii) supply chain management, and (iii) other value-added services.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.